Glucagon
You might not need it, but you need to know it’s there.

Glucagon is a treatment for insulin coma or insulin reaction resulting from severe low blood sugar.

Who should not use Glucagon?
Glucagon should not be used if your child has pheochromocytoma or if he/she is allergic to Glucagon.

Please see Important Safety Information on pages 17-19. For more information, please see Information for the User and Information for the Physician included with this brochure.
Just in Case

Sometimes your child might miss a meal, exercise too much, or not eat enough food for the amount of insulin he/she has taken. Any of these situations can lead to low blood sugar, also called hypoglycemia.

If not treated quickly, mild or moderate low blood sugar can become severe. In these cases, your child may be physically unable to eat or drink a rapid acting source of glucose or may lose consciousness. You will need to give your child a Glucagon shot immediately.

Glucagon is a medicine that's different from insulin. It works by telling the body to release sugar (glucose) into the blood stream to bring the blood sugar level back up.

The possibility of severe low blood sugar and of giving your child a Glucagon injection can be scary. But it’s very important that you understand how to recognize symptoms of severe low blood sugar and that you’re ready to give a Glucagon injection, if you have to.

Making sure there’s a Lilly Glucagon™ Emergency Kit wherever you need one and that it’s not expired is important. Practicing the steps ahead of time can help you feel more comfortable in the situation.

Select Safety Information

- You and anyone who may need to help your child during an emergency should become familiar with how to use Glucagon before an emergency arises. Read the Information for the User provided in the kit.

To learn more about Glucagon and how it can help you be better prepared, go to LillyGlucagon.com.
Ask your child’s healthcare provider about prescribing more than one Lilly Glucagon Emergency Kit for severe low blood sugar.

Many insurance plans allow you to receive more than one kit with only one co-pay. Check with your insurance provider or your pharmacist to find out how many kits you can get with a single co-pay.

That way, you can have one at home, one at school (with the school nurse), and one wherever else your child spends time.

It’s a good idea to pack a Glucagon kit with your child’s other diabetes supplies whenever they’re away from home or school, such as:

- Sports
- School trips
- After-school activities
- Visiting friends or relatives
- Vacations
- Summer camp

Instructions for Use

1. Flip off the seal from the vial of Glucagon powder.

2. Remove the needle cover from the syringe. DO NOT REMOVE THE PLASTIC CLIP FROM THE SYRINGE, as this may allow the push rod to come out of the syringe.

3. Insert the needle into the rubber stopper on the vial, then inject the entire contents of the syringe into the vial of Glucagon powder.

(continued on next page)

These are not the complete instructions. For complete instructions on how to administer Glucagon, please see Information for the User included with this brochure.

Please see Important Safety Information on pages 17-19. For more information, please see Information for the User and Information for the Physician included with this brochure.

Visit LillyGlucagon.com
4. Remove the syringe from the vial, then gently swirl the vial until the liquid becomes clear. Glucagon should not be used unless the solution is clear and of a water-like consistency.

5. Insert the same syringe into the vial and slowly withdraw all of the liquid. In children weighing less than 44 pounds, withdraw half the liquid (0.5 mark on the syringe).

6. Cleanse site on buttock, arm, or thigh and inject Glucagon immediately after mixing, and then withdraw the needle. Apply light pressure against the injection site.

7. Turn the child on his/her side. When an unconscious person awakens, he/she may vomit. Call 911 immediately after administering Glucagon. If the child does not awaken within 15 minutes, you may administer a second dose of Glucagon, if previously instructed by your child’s healthcare provider to do so.

As soon as the child is awake and able to swallow, give him/her a fast-acting source of sugar (such as fruit juice) followed by a snack or meal containing both protein and carbohydrates (such as cheese and crackers, or a peanut butter sandwich).


Remember to notify your child’s healthcare provider that an episode of severe hypoglycemia has occurred.

These are not the complete instructions. For complete instructions on how to administer Glucagon, please see Information for the User included with this brochure.

Please see Important Safety Information on pages 17-19. For more information, please see Information for the User and Information for the Physician included with this brochure.

Visit LillyGlucagon.com
Be Prepared

• Glucagon is a potentially lifesaving treatment for episodes of severe low blood sugar.

• The Lilly Glucagon Emergency Kit is small and portable, keeps all the items needed to administer Glucagon, and comes packaged in a bright red case.

• The usual dosing amount varies between adults and children (dosing is based on body weight). Ask your child’s healthcare provider about the correct dosing amount for your child.*

*The usual adult dose is 1 mg (1 unit). For children weighing less than 44 lbs (20 kg), give 1/2 of the adult dose (0.5 mg), by withdrawing 1/2 of the solution from the bottle (0.5 mg mark on syringe). Discard unused portion.

Select Safety Information

• Tell your child’s doctor about all of his or her medical conditions and prescription and over-the-counter drugs.
• Make sure that your relatives or close friends know that if your child becomes unconscious, medical assistance must always be sought. If your child is unconscious, Glucagon can be given while awaiting medical assistance.
• If you have questions concerning the use of this product, consult a doctor, nurse or pharmacist.

WARNING: YOUR CHILD MAY BE IN A COMA FROM SEVERE HYPERGLYCEMIA (HIGH BLOOD GLUCOSE) RATHER THAN HYPOGLYCEMIA, IN SUCH A CASE, YOUR CHILD WILL NOT RESPOND TO GLUCAGON AND REQUIRES IMMEDIATE MEDICAL ATTENTION.

Please see Important Safety Information on pages 17-19. For more information, please see Information for the User and Information for the Physician included with this brochure. Visit LillyGlucagon.com
Use These Reminders

They’ll help friends, relatives, babysitters, you, and anyone else looking after your child remember where their Glucagon is located and when it expires.

Tear off one of the attached cards and fill in the location of your Lilly Glucagon Emergency Kits and the expiration dates. Then place the card in a visible spot, or attach it to something around your home or workplace, like near the telephone, on the refrigerator, or next to your computer screen.

Use the additional cards when you change the location of your kits or when you replace an expired kit.

Another easy way to keep track of your Lilly Glucagon Emergency Kits is with our free smartphone app. Turn the page to learn more.
Info in Your Hands

With the Glucagon app, you have the information you need right on your device.

See how the Glucagon app can help you be prepared on the next page...

Apple®, the Apple logo and iPhone® are trademarks of Apple Inc., registered in the US and other countries. App StoreSM is a service mark of Apple Inc.

Please see Important Safety Information on pages 17-19. For more information, please see Information for the User and Information for the Physician included with this brochure.

Visit LillyGlucagon.com
Info in Your Hands

Download the Glucagon smartphone app to help prepare yourself in case your child ever experiences a severe low blood sugar episode. It’s also a great way to help family and friends be better prepared to use Glucagon.

Go to LillyGlucagon.com and learn how the app can help you:

- **Virtual practice**: Walk through each step of administering Glucagon, using the touchscreen simulator
- **Keep track**: Record the locations and expiration dates of all your Glucagon kits in the kit log. Notifications will remind you when a kit is due to expire soon so that you can replace it in time
- **Be informed**: Review quick tips that offer more information about how to be better prepared in case of an extreme low blood sugar episode
- **Use Glucagon in an emergency**: Step-by-step guidance, including an audio option, can help you follow the instructions in case of a real low blood sugar emergency

Select Safety Information

- Make sure that your relatives or close friends know that if your child becomes unconscious, medical assistance must always be sought. If your child is unconscious, Glucagon can be given while awaiting medical assistance.

To learn more about this free app, visit LillyGlucagon.com today.

Apple®, the Apple logo and iPhone® are trademarks of Apple Inc., registered in the US and other countries. App Store™ is a service mark of Apple Inc.
Important Safety Information for Glucagon

What is the most important information I should know about Glucagon?

• Glucagon should not be used if you have pheochromocytoma or if you are allergic to Glucagon.
• Make sure you tell your healthcare provider if you have been diagnosed with or have been suspected of having an insulinoma as Glucagon should be used cautiously in this situation.
• You and anyone who may need to help you during an emergency should become familiar with how to use Glucagon before an emergency arises. Read the Information for the User provided in the kit.
• Make sure that your relatives or close friends know that if you become unconscious, medical assistance must always be sought. If you are unconscious, Glucagon can be given while awaiting medical assistance.
• Do not use the kit after the date stamped on the bottle label.
• If you have questions concerning the use of this product, consult a doctor, nurse or pharmacist.

WARNING: YOU MAY BE IN A COMA FROM SEVERE HYPERGLYCEMIA (HIGH BLOOD GLUCOSE) RATHER THAN HYPOGLYCEMIA. IN SUCH A CASE, YOU WILL NOT RESPOND TO GLUCAGON AND REQUIRE IMMEDIATE MEDICAL ATTENTION.

Who should not use Glucagon?
Glucagon should not be used if you have pheochromocytoma or if you are allergic to Glucagon.

(continued on next page)
Important Safety Information for Glucagon (continued)

What should I tell my doctor before taking Glucagon?
Tell your doctor about all of your medical conditions and prescription and over-the-counter drugs. Tell your doctor if you have been diagnosed with or have been suspected of having pheochromocytoma or an insulinoma.

How should I use Glucagon?
• Act quickly. Prolonged unconsciousness may be harmful.
• Make sure your family and friends know to turn you on your side to prevent choking if you are unconscious.
• The contents of the syringe are inactive and must be mixed with the Glucagon in the accompanying bottle immediately before giving injection. Do not prepare Glucagon for injection until you are ready to use it.
• Glucagon should not be used unless the solution is clear and of a water-like consistency.
• The usual adult dose is 1 mg (1 unit). For children weighing less than 44 lbs (20 kg), give 1/2 adult dose (0.5 mg). For children, withdraw 1/2 of the solution from the bottle (0.5 mg mark on syringe). Discard unused portion.
• You should eat as soon as you awaken and are able to swallow. Inform a doctor or emergency services immediately.

What is some important information I should know about Low Blood Sugar (Hypoglycemia)?
• Early symptoms of low blood sugar include: sweating, drowsiness, dizziness, sleep disturbances, palpitation, anxiety, tremor, blurred vision, hunger, slurred speech, restlessness, depressed mood, tingling in the hands, feet, lips, or tongue, irritability, lightheadedness, abnormal behavior, inability to concentrate, unsteady movement, headache, and personality changes. These symptoms may be different for each person and can happen suddenly.

• If your low blood sugar is not treated, you may progress to severe low blood sugar that can include: disorientation, seizures, unconsciousness, and death.
• Low blood sugar symptoms should be treated with a quick source of sugar which should always be carried with you. If you do not improve or you are unable to take a quick source of sugar, you should be treated with Glucagon or with intravenous glucose at a medical facility.

What are the possible side effects of Glucagon?
• Severe side effects are very rare, although nausea and vomiting may occur occasionally.
• A few people may be allergic to Glucagon or to one of the inactive ingredients in Glucagon, or may experience rapid heart beat for a short while.
• If you experience any other reactions which are likely to have been caused by Glucagon, please contact your doctor.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

How should I store Glucagon?
• Before dissolving Glucagon with diluting solution, store the kit at controlled room temperature between 20° to 25°C (68° to 77°F).
• After dissolving Glucagon with diluting solution, use immediately. Discard any unused portion. Glucagon should be clear and of a water-like consistency at time of use.

Glucagon is available by prescription only.

For more safety information, please see Information for the User and Information for the Physician included with this brochure.
Glucagon
You might not need it, but you need to know it’s there.
LillyGlucagon.com
INFORMATION FOR THE USER

GLUCAGON
FOR INJECTION
(rDNA ORIGIN)

BECOME FAMILIAR WITH THE FOLLOWING INSTRUCTIONS BEFORE AN EMERGENCY ARISES. DO NOT USE THIS KIT AFTER DATE STAMPED ON THE BOTTLE LABEL. IF YOU HAVE QUESTIONS CONCERNING THE USE OF THIS PRODUCT, CONSULT A DOCTOR, NURSE OR PHARMACIST.

Make sure that your relatives or close friends know that if you become unconscious, medical assistance must always be sought. Glucagon may have been prescribed so that members of your household can give the injection if you become hypoglycemic and are unable to take sugar by mouth. If you are unconscious, glucagon can be given while awaiting medical assistance.

Show your family members and others where you keep this kit and how to use it. They need to know how to use it before you need it. They can practice giving a shot by giving you your normal insulin shots. It is important that they practice. A person who has never given a shot probably will not be able to do it in an emergency.

IMPORTANT
• Act quickly. Prolonged unconsciousness may be harmful.
• These simple instructions will help you give glucagon successfully.
• Turn patient on his/her side to prevent patient from choking.
• The contents of the syringe are inactive. You must mix the contents of the syringe with the glucagon in the accompanying bottle before giving injection. (See DIRECTIONS FOR USE below.)
• Do not prepare Glucagon for Injection until you are ready to use it.

WARNING: THE PATIENT MAY BE IN A COMA FROM SEVERE HYPERGLYCEMIA (HIGH BLOOD GLUCOSE) RATHER THAN HYPOGLYCEMIA. IN SUCH A CASE, THE PATIENT WILL NOT RESPOND TO GLUCAGON AND REQUIRES IMMEDIATE MEDICAL ATTENTION.

INDICATIONS FOR USE
Use glucagon to treat insulin coma or insulin reaction resulting from severe hypoglycemia (low blood sugar). Symptoms of severe hypoglycemia include disorientation, unconsciousness, and seizures or convulsions. Give glucagon if (1) the patient is unconscious (2) the patient is unable to eat sugar or a sugar-sweetened product (3) the patient is having a seizure, or (4) repeated administration of sugar or a sugar-sweetened product such as a regular soft drink or fruit juice does not improve the patient’s condition. Milder cases of hypoglycemia should be treated promptly by eating sugar or a sugar-sweetened product. (See INFORMATION ON HYPOGLYCEMIA below for more information on the symptoms of hypoglycemia.) Glucagon is not active when taken orally.

DIRECTIONS FOR USE
TO PREPARE GLUCAGON FOR INJECTION
1. Remove the flip-off seal from the bottle of glucagon. Wipe rubber stopper on bottle with alcohol swab.
2. Remove the needle protector from the syringe, and inject the entire contents of the syringe into the bottle of glucagon. DO NOT REMOVE THE PLASTIC CLIP FROM THE SYRINGE. Remove syringe from the bottle.

3. Swirl bottle gently until glucagon dissolves completely. GLUCAGON SHOULD NOT BE USED UNLESS THE SOLUTION IS CLEAR AND OF A WATER-LIKE CONSISTENCY.

**TO INJECT GLUCAGON**

*Use Same Technique as for Injecting Insulin*

4. Using the same syringe, hold bottle upside down and, making sure the needle tip remains in solution, gently withdraw all of the solution (1 mg mark on syringe) from bottle. The plastic clip on the syringe will prevent the rubber stopper from being pulled out of the syringe; however, if the plastic plunger rod separates from the rubber stopper, simply reinsert the rod by turning it clockwise. The usual adult dose is 1 mg (1 unit). For children weighing less than 44 lb (20 kg), give 1/2 adult dose (0.5 mg). For children, withdraw 1/2 of the solution from the bottle (0.5 mg mark on syringe). DISCARD UNUSED PORTION.
USING THE FOLLOWING DIRECTIONS, INJECT GLUCAGON IMMEDIATELY AFTER MIXING.

5. Cleanse injection site on buttock, arm, or thigh with alcohol swab.
6. Insert the needle into the loose tissue under the cleansed injection site, and inject all (or 1/2 for children weighing less than 44 lb) of the glucagon solution. THERE IS NO DANGER OF OVERDOSE. Apply light pressure at the injection site, and withdraw the needle. Press an alcohol swab against the injection site.
7. Turn the patient on his/her side. When an unconscious person awakens, he/she may vomit. Turning the patient on his/her side will prevent him/her from choking.
8. FEED THE PATIENT AS SOON AS HE/SHE AWAKENS AND ISABLE TO SWALLOW. Give the patient a fast-acting source of sugar (such as a regular soft drink or fruit juice) and a long-acting source of sugar (such as crackers and cheese or a meat sandwich). If the patient does not awaken within 15 minutes, give another dose of glucagon and INFORM A DOCTOR OR EMERGENCY SERVICES IMMEDIATELY.
9. Even if the glucagon revives the patient, his/her doctor should be promptly notified. A doctor should be notified whenever severe hypoglycemic reactions occur.

INFORMATION ON HYPOGLYCEMIA

Early symptoms of hypoglycemia (low blood glucose) include:

- sweating
- dizziness
- palpitation
- tremor
- hunger
- restlessness
- tingling in the hands, feet, lips, or tongue
- lightheadedness
- inability to concentrate
- headache

If not treated, the patient may progress to severe hypoglycemia that can include:

- drowsiness
- sleep disturbances
- anxiety
- blurred vision
- slurred speech
- depressed mood
- irritability
- abnormal behavior
- unsteady movement
- personality changes

The occurrence of early symptoms calls for prompt and, if necessary, repeated administration of some form of carbohydrate. Patients should always carry a quick source of sugar, such as candy mints or glucose tablets. The prompt treatment of mild hypoglycemic symptoms can prevent severe hypoglycemic reactions. If the patient does not improve or if administration of carbohydrate is impossible, glucagon should be given or the patient should be treated with intravenous glucose at a medical facility. Glucagon, a naturally occurring substance produced by the pancreas, is helpful because it enables the patient to produce his/her own blood glucose to correct the hypoglycemia.
POSSIBLE PROBLEMS WITH GLUCAGON TREATMENT
Severe side effects are very rare, although nausea and vomiting may occur occasionally.
A few people may be allergic to glucagon or to one of the inactive ingredients in glucagon, or
may experience rapid heart beat for a short while.
If you experience any other reactions which are likely to have been caused by glucagon, please
contact your doctor.

STORAGE
Before dissolving glucagon with diluting solution — Store the kit at controlled room
temperature between 20° to 25°C (68° to 77°F).
After dissolving glucagon with diluting solution — Should be used immediately. Discard any
unused portion. Solutions should be clear and of a water-like consistency at time of use.

Literature revised September 19, 2012
Marketed by: Lilly USA, LLC
Indianapolis, IN 46285, USA
PA 2286 AMP
Copyright © 1999, 2012, Eli Lilly and Company. All rights reserved.
INFORMATION FOR THE PHYSICIAN

GLUCAGON FOR INJECTION (rDNA ORIGIN)

DESCRIPTION

Glucagon for Injection (rDNA origin) is a polypeptide hormone identical to human glucagon that increases blood glucose and relaxes smooth muscle of the gastrointestinal tract. Glucagon is synthesized in a special non-pathogenic laboratory strain of *Escherichia coli* bacteria that has been genetically altered by the addition of the gene for glucagon.

Glucagon is a single-chain polypeptide that contains 29 amino acid residues and has a molecular weight of 3483.

The empirical formula is C\textsubscript{153}H\textsubscript{225}N\textsubscript{43}O\textsubscript{49}S. The primary sequence of glucagon is shown below.

![Primary sequence of glucagon](image)

Crystalline glucagon is a white to off-white powder. It is relatively insoluble in water but is soluble at a pH of less than 3 or more than 9.5.

Glucagon is available for use intravenously, intramuscularly, or subcutaneously in a kit that contains a vial of sterile glucagon and a syringe of sterile diluent. The vial contains 1 mg (1 unit) of glucagon and 49 mg of lactose. Hydrochloric acid may have been added during manufacture to adjust the pH of the glucagon. One International Unit of glucagon is equivalent to 1 mg of glucagon.\(^1\) The diluent syringe contains 12 mg/mL of glycerin, Water For Injection, and hydrochloric acid.

CLINICAL PHARMACOLOGY

Glucagon increases blood glucose concentration and is used in the treatment of hypoglycemia. Glucagon acts only on liver glycogen, converting it to glucose.

Glucagon administered through a parenteral route relaxes smooth muscle of the stomach, duodenum, small bowel, and colon.

Pharmacokinetics

Glucagon has been studied following intramuscular, subcutaneous, and intravenous administration in adult volunteers. Administration of the intravenous glucagon showed dose proportionality of the pharmacokinetics between 0.25 and 2.0 mg. Calculations from a 1 mg dose showed a small volume of distribution (mean, 0.25 L/kg) and a moderate clearance (mean, 13.5 mL/min/kg). The half-life was short, ranging from 8 to 18 minutes.

Maximum plasma concentrations of 7.9 ng/mL were achieved approximately 20 minutes after subcutaneous administration (see Figure 1A). With intramuscular dosing, maximum plasma concentrations of 6.9 ng/mL were attained approximately 13 minutes after dosing.

Glucagon is extensively degraded in liver, kidney, and plasma. Urinary excretion of intact glucagon has not been measured.
Pharmacodynamics

In a study of 25 volunteers, a subcutaneous dose of 1 mg glucagon resulted in a mean peak glucose concentration of 136 mg/dL 30 minutes after injection (see Figure 1B). Similarly, following intramuscular injection, the mean peak glucose level was 138 mg/dL, which occurred at 26 minutes after injection. No difference in maximum blood glucose concentration between animal-sourced and rDNA glucagon was observed after subcutaneous and intramuscular injection.

Figure 1
Mean (±SE) serum glucagon and blood glucose levels after subcutaneous injection of glucagon (1 mg) in 25 normal volunteers

A

B

INDICATIONS AND USAGE

For the treatment of hypoglycemia:

Glucagon is indicated as a treatment for severe hypoglycemia.

Because patients with type 1 diabetes may have less of an increase in blood glucose levels compared with a stable type 2 patient, supplementary carbohydrate should be given as soon as possible, especially to a pediatric patient.
For use as a diagnostic aid:

Glucagon is indicated as a diagnostic aid in the radiologic examination of the stomach, duodenum, small bowel, and colon when diminished intestinal motility would be advantageous. Glucagon is as effective for this examination as are the anticholinergic drugs. However, the addition of the anticholinergic agent may result in increased side effects.

**CONTRAINDICATIONS**

Glucagon is contraindicated in patients with known hypersensitivity to it or in patients with known pheochromocytoma.

**WARNINGS**

Glucagon should be administered cautiously to patients with a history suggestive of insulinoma, pheochromocytoma, or both. In patients with insulinoma, intravenous administration of glucagon may produce an initial increase in blood glucose; however, because of glucagon’s hyperglycemic effect the insulinoma may release insulin and cause subsequent hypoglycemia. A patient developing symptoms of hypoglycemia after a dose of glucagon should be given glucose orally, intravenously, or by gavage, whichever is most appropriate.

Exogenous glucagon also stimulates the release of catecholamines. In the presence of pheochromocytoma, glucagon can cause the tumor to release catecholamines, which may result in a sudden and marked increase in blood pressure. If a patient develops a sudden increase in blood pressure, 5 to 10 mg of phentolamine mesylate may be administered intravenously in an attempt to control the blood pressure.

Generalized allergic reactions, including urticaria, respiratory distress, and hypotension, have been reported in patients who received glucagon by injection.

**PRECAUTIONS**

**General**

Glucagon is effective in treating hypoglycemia only if sufficient liver glycogen is present. Because glucagon is of little or no help in states of starvation, adrenal insufficiency, or chronic hypoglycemia, hypoglycemia in these conditions should be treated with glucose.

**Information for Patients**

Refer patients and family members to the attached Information for the User for instructions describing the method of preparing and injecting glucagon. Advise the patient and family members to become familiar with the technique of preparing glucagon before an emergency arises. Instruct patients to use 1 mg (1 unit) for adults and 1/2 the adult dose (0.5 mg) [0.5 unit] for pediatric patients weighing less than 44 lb (20 kg).

Patients and family members should be informed of the following measures to prevent hypoglycemic reactions due to insulin:

1. Reasonable uniformity from day to day with regard to diet, insulin, and exercise.
2. Careful adjustment of the insulin program so that the type (or types) of insulin, dose, and time (or times) of administration are suited to the individual patient.
3. Frequent testing of the blood or urine for glucose so that a change in insulin requirements can be foreseen.
4. Routine carrying of sugar, candy, or other readily absorbable carbohydrate by the patient so that it may be taken at the first warning of an oncoming reaction.

To prevent severe hypoglycemia, patients and family members should be informed of the symptoms of mild hypoglycemia and how to treat it appropriately.

Family members should be informed to arouse the patient as quickly as possible because prolonged hypoglycemia may result in damage to the central nervous system. Glucagon or intravenous glucose should awaken the patient sufficiently so that oral carbohydrates may be taken.

Patients should be advised to inform their physician when hypoglycemic reactions occur so that the treatment regimen may be adjusted if necessary.
Laboratory Tests

Blood glucose determinations should be obtained to follow the patient with hypoglycemia until patient is asymptomatic.

Carcinogenesis, Mutagenesis, Impairment of Fertility

Because glucagon is usually given in a single dose and has a very short half-life, no studies have been done regarding carcinogenesis. In a series of studies examining effects on the bacterial mutagenesis (Ames) assay, it was determined that an increase in colony counts was related to technical difficulties in running this assay with peptides and was not due to mutagenic activities of the glucagon.

Reproduction studies have been performed in rats at doses up to 2 mg/kg glucagon administered two times a day (up to 40 times the human dose based on body surface area, mg/m²) and have revealed no evidence of impaired fertility.

Pregnancy

Pregnancy Category B — Reproduction studies have not been performed with recombinant glucagon. However, studies with animal-sourced glucagon were performed in rats at doses up to 2 mg/kg glucagon administered two times a day (up to 40 times the human dose based on body surface area, mg/m²), and have revealed no evidence of impaired fertility or harm to the fetus due to glucagon. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.

Nursing Mothers

It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when glucagon is administered to a nursing woman. If the drug is excreted in human milk during its short half-life, it will be hydrolyzed and absorbed like any other polypeptide. Glucagon is not active when taken orally because it is destroyed in the gastrointestinal tract before it can be absorbed.

Pediatric Use

For the treatment of hypoglycemia: The use of glucagon in pediatric patients has been reported to be safe and effective.

For use as a diagnostic aid: Effectiveness has not been established in pediatric patients.

Geriatric Use

Clinical studies of glucagon did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

ADVERSE REACTIONS

Severe adverse reactions are very rare, although nausea and vomiting may occur occasionally. These reactions may also occur with hypoglycemia. Generalized allergic reactions have been reported (see WARNINGS). In a three month controlled study of 75 volunteers comparing animal-sourced glucagon with glucagon manufactured through rDNA technology, no glucagon-specific antibodies were detected in either treatment group.

OVERDOSAGE

Signs and Symptoms — If overdosage occurs, nausea, vomiting, gastric hypotonicity, and diarrhea would be expected without causing consequential toxicity.

Intravenous administration of glucagon has been shown to have positive inotropic and chronotropic effects. A transient increase in both blood pressure and pulse rate may occur following the administration of glucagon. Patients taking β-blockers might be expected to have a greater increase in both pulse and blood pressure, an increase of which will be transient because
of glucagon’s short half-life. The increase in blood pressure and pulse rate may require therapy in patients with pheochromocytoma or coronary artery disease.

When glucagon was given in large doses to patients with cardiac disease, investigators reported a positive inotropic effect. These investigators administered glucagon in doses of 0.5 to 16 mg/hour by continuous infusion for periods of 5 to 166 hours. Total doses ranged from 25 to 996 mg, and a 21-month-old infant received approximately 8.25 mg in 165 hours. Side effects included nausea, vomiting, and decreasing serum potassium concentration. Serum potassium concentration could be maintained within normal limits with supplemental potassium.

The intravenous median lethal dose for glucagon in mice and rats is approximately 300 mg/kg and 38.6 mg/kg, respectively. Because glucagon is a polypeptide, it would be rapidly destroyed in the gastrointestinal tract if it were to be accidentally ingested.

Treatment — To obtain up-to-date information about the treatment of overdose, a good resource is your certified Regional Poison Control Center. Telephone numbers of certified poison control centers are listed in the *Physicians’ Desk Reference (PDR)*. In managing overdosage, consider the possibility of multiple drug overdoses, interaction among drugs, and unusual drug kinetics in your patient.

In view of the extremely short half-life of glucagon and its prompt destruction and excretion, the treatment of overdosage is symptomatic, primarily for nausea, vomiting, and possible hypokalemia.

If the patient develops a dramatic increase in blood pressure, 5 to 10 mg of phentolamine mesylate has been shown to be effective in lowering blood pressure for the short time that control would be needed.

Forced diuresis, peritoneal dialysis, hemodialysis, or charcoal hemoperfusion have not been established as beneficial for an overdose of glucagon; it is extremely unlikely that one of these procedures would ever be indicated.

**DOSAGE AND ADMINISTRATION**

*General Instructions for Use:*

- The diluent is provided for use only in the preparation of glucagon for parenteral injection and for no other use.
- Glucagon should not be used at concentrations greater than 1 mg/mL (1 unit/mL).
- Reconstituted glucagon should be used immediately. **Discard any unused portion.**
- Reconstituted glucagon solutions should be used only if they are clear and of a water-like consistency.
- Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration.

*Directions for Treatment of Severe Hypoglycemia:*

Severe hypoglycemia should be treated initially with intravenous glucose, if possible.

1. If parenteral glucose can not be used, dissolve the lyophilized glucagon using the accompanying diluting solution and use immediately.
2. For adults and for pediatric patients weighing more than 44 lb (20 kg), give 1 mg (1 unit) by subcutaneous, intramuscular, or intravenous injection.
3. For pediatric patients weighing less than 44 lb (20 kg), give 0.5 mg (0.5 unit) or a dose equivalent to 20 to 30 µg/kg.

4. **Discard any unused portion.**
5. An unconscious patient will usually awaken within 15 minutes following the glucagon injection. If the response is delayed, there is no contraindication to the administration of an additional dose of glucagon; however, in view of the deleterious effects of cerebral hypoglycemia emergency aid should be sought so that parenteral glucose can be given.
6. After the patient responds, supplemental carbohydrate should be given to restore liver glycogen and to prevent secondary hypoglycemia.
Directions for Use as a Diagnostic Aid:

Dissolve the lyophilized glucagon using the accompanying diluting solution and use immediately. **Discard any unused portion.**

The doses in the following table may be administered for relaxation of the stomach, duodenum, and small bowel, depending on the onset and duration of effect required for the examination. Since the stomach is less sensitive to the effect of glucagon, 0.5 mg (0.5 units) IV or 2 mg (2 units) IM are recommended.

<table>
<thead>
<tr>
<th>Dose</th>
<th>Route of Administration</th>
<th>Time of Onset of Action</th>
<th>Approximate Duration of Effect</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.25-0.5 mg (0.25-0.5 units)</td>
<td>IV</td>
<td>1 minute</td>
<td>9-17 minutes</td>
</tr>
<tr>
<td>1 mg (1 unit)</td>
<td>IM</td>
<td>8-10 minutes</td>
<td>12-27 minutes</td>
</tr>
<tr>
<td>2 mg (2 units)</td>
<td>IV</td>
<td>1 minute</td>
<td>22-25 minutes</td>
</tr>
<tr>
<td>2 mg (2 units)</td>
<td>IM</td>
<td>4-7 minutes</td>
<td>21-32 minutes</td>
</tr>
</tbody>
</table>

* Administration of 2 mg (2 units) doses produces a higher incidence of nausea and vomiting than do lower doses.

For examination of the colon, it is recommended that a 2 mg (2 units) dose be administered intramuscularly approximately 10 minutes prior to the procedure. Colon relaxation and reduction of patient discomfort may allow the radiologist to perform a more satisfactory examination.

**HOW SUPPLIED**

Glucagon Emergency Kit for Low Blood Sugar (Glucagon for Injection [rDNA origin]) (MS8031):

1 mg (1 unit) — (VL7529), with 1 mL of diluting solution (Hyporet®* HY7530) (1s)
NDC 0002-8031-01

* Hyporet® (disposable syringe, Lilly).

**Stability and Storage:**

**Before Reconstitution** — Vials of Glucagon, as well as the Diluting Solution for Glucagon, may be stored at controlled room temperature 20° to 25°C (68° to 77°F)[see USP].

The USP defines controlled room temperature by the following: A temperature maintained thermostatically that encompasses the usual and customary working environment of 20° to 25°C (68° to 77°F); that results in a mean kinetic temperature calculated to be not more than 25°C; and that allows for excursions between 15° and 30°C (59° and 86°F) that are experienced in pharmacies, hospitals, and warehouses.

**After Reconstitution** — Glucagon for Injection (rDNA origin) should be used immediately. **Discard any unused portion.**

**REFERENCES**


Literature revised September 19, 2012

**Marketed by: Lilly USA, LLC**
**Indianapolis, IN 46285, USA**

PA 2286 AMP

Copyright © 1999, 2012, Eli Lilly and Company. All rights reserved.